An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia

Avani Lamba, Thomas M. Roston, Puck J. Peltenburg, Dania Kallas, Sonia Franciosi, Krystien V.V. Lieve, Prince J. Kannankeril, Minoru Horie, Seiko Ohno, Ramon Brugada, Takeshi Aiba, Peter Fischbach, Linda Knight, Jan Till, Sit Yee Kwok, Vincent Probst, David Backhoff, Martin J. LaPage, Anjan S. Batra, Fabrizio DragoKristina Haugaa, Andrew D. Krahn, Tomas Robyns, Heikki Swan, Terezia Tavacova, Christian van der Werf, Joseph Atallah, Martin Borggrefe, Boris Rudic, Georgia Sarquella-Brugada, Ehud Chorin, Allison Hill, Janneke Kammeraad, Anna Kamp, Ian Law, James Perry, Jason D. Roberts, Svjetlana Tisma-Dupanovic, Christopher Semsarian, Jonathan R. Skinner, Jacob Tfelt-Hansen, Isabelle Denjoy, Antoine Leenhardt, Peter J. Schwartz, Michael J. Ackerman, Arthur A.M. Wilde, Nico A. Blom, Shubhayan Sanatani*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) may cause sudden cardiac death (SCD) despite medical therapy. Therefore, implantable cardioverter-defibrillators (ICDs) are commonly advised. However, there is limited data on the outcomes of ICD use in children. Objective: The purpose of this study was to compare the risk of arrhythmic events in pediatric patients with CPVT with and without an ICD. Methods: We compared the risk of SCD in patients with RYR2 (ryanodine receptor 2) variants and phenotype-positive symptomatic CPVT patients with and without an ICD who were younger than 19 years and had no history of sudden cardiac arrest at phenotype diagnosis. The primary outcome was SCD; secondary outcomes were composite end points of SCD, sudden cardiac arrest, or appropriate ICD shocks with or without arrhythmic syncope. Results: The study included 235 patients, 73 with an ICD (31.1%) and 162 without an ICD (68.9%). Over a median follow-up of 8.0 years (interquartile range 4.3–13.4 years), SCD occurred in 7 patients (3.0%), of whom 4 (57.1%) were noncompliant with medications and none had an ICD. Patients with ICD had a higher risk of both secondary composite outcomes (without syncope: hazard ratio 5.85; 95% confidence interval 3.40–10.09; P < .0001; with syncope: hazard ratio 2.55; 95% confidence interval 1.50–4.34; P = .0005). Thirty-one patients with ICD (42.5%) experienced appropriate shocks, 18 (24.7%) inappropriate shocks, and 21 (28.8%) device-related complications. Conclusion: SCD events occurred only in patients without an ICD and mostly in those not on optimal medical therapy. Patients with an ICD had a high risk of appropriate and inappropriate shocks, which may be reduced with appropriate device programming. Severe ICD complications were common, and risks vs benefits of ICDs need to be considered.

Original languageEnglish
JournalHeart Rhythm
DOIs
StateAccepted/In press - 2024

Funding

FundersFunder number
ZonMW Priority Medicines for Rare Diseases
Ministerstvo Zdravotnictví Ceské Republiky
Dutch Heart Foundation
AEPC
University of British Columbia
Royal Netherlands Academy of Sciences
Netherlands Organisation for Health Research and Development
Dutch Federation of University Medical Centres
Ministry of Health, Czech Republic
Heart and Stroke Foundation of Canada
Motol University Hospital00064203
National Health and Medical Research Council2016822
National Health and Medical Research Council
Heart and Stroke Foundation of CanadaG-19-0024239, G-9003037609, G-15-0008870
Heart and Stroke Foundation of Canada
Orphan Drugs113304045

    Keywords

    • Catecholaminergic polymorphic ventricular tachycardia
    • Implantable cardioverter-defibrillator
    • Inherited arrhythmia
    • Ryanodine receptor
    • Sudden cardiac death
    • Ventricular tachycardia

    Fingerprint

    Dive into the research topics of 'An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia'. Together they form a unique fingerprint.

    Cite this